Asset Details
Do you wish to reserve the book?
Unrestricted public coverage is needed for smoking cessation pharmacotherapies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Unrestricted public coverage is needed for smoking cessation pharmacotherapies
Do you wish to request the book?
Unrestricted public coverage is needed for smoking cessation pharmacotherapies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Unrestricted public coverage is needed for smoking cessation pharmacotherapies
2024
Overview
Tobacco use is a leading cause of preventable death in Canada, and it is time for governments to ensure that all people with provincial drug benefits have access to smoking cessation medications. Pharmacotherapies are effective for smoking cessation. In a phase-4 randomized controlled trial, people treated with varenicline for 12 weeks had cessation rates of 22% at 24 weeks compared with 9% among those receiving placebo. Meta-analyses have found that combination nicotine replacement therapy, which combines the nicotine patch with a short-acting nicotine formulation, has similar cessation rates to varenicline. Cytisine is a smoking cessation pharmacotherapy with similar effect sizes to varenicline. Bupropion has smaller effect sizes than varenicline but is superior to placebo in helping people stop smoking.
Publisher
Elsevier Inc,CMA Impact Inc,CMA Impact, Inc
